Sciclone Pharma (SCLN) Tops Q1 EPS by 17c

Sciclone Pharma (NASDAQ: SCLN) reported Q1 EPS of $0.31, $0.17 better than the analyst estimate of $0.14. Revenue for the quarter came in at $42.9 million versus the consensus estimate of $39.94 million.

• Revenues: In the first quarter 2017, SciClone reported revenues of $42.9 million, compared to $36.5 million for the same period in 2016.
• GAAP Diluted EPS: In the first quarter 2017, SciClone reported GAAP diluted earnings per share of $0.28, compared to $0.15 for the same period in 2016.
• Non-GAAP Diluted EPS: In the first quarter 2017, SciClone reported non-GAAP diluted earnings per share of $0.31, compared to $0.19 for the same period in 2016.

For earnings history and earnings-related data on Sciclone Pharma (SCLN) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c
• CaliberCos Inc (CWD) Misses Q2 EPS by 43c; Offers Guidance